HNP Capital LLC trimmed its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 17.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,068 shares of the medical research company’s stock after selling 233 shares during the period. HNP Capital LLC’s holdings in Amgen were worth $206,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Advisors Preferred LLC acquired a new position in shares of Amgen in the second quarter valued at $30,000. Arbor Wealth Management LLC increased its holdings in shares of Amgen by 154.5% in the second quarter. Arbor Wealth Management LLC now owns 168 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 102 shares during the last quarter. Ashburton Jersey Ltd acquired a new position in shares of Amgen in the second quarter valued at $42,000. Sound Income Strategies LLC increased its holdings in shares of Amgen by 402.1% in the second quarter. Sound Income Strategies LLC now owns 236 shares of the medical research company’s stock valued at $43,000 after purchasing an additional 189 shares during the last quarter. Finally, Next Capital Management LLC increased its holdings in shares of Amgen by 42.5% in the second quarter. Next Capital Management LLC now owns 238 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 71 shares during the last quarter. Institutional investors and hedge funds own 76.24% of the company’s stock.
In related news, SVP Cynthia M. Patton sold 13,426 shares of the company’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $208.07, for a total transaction of $2,793,547.82. Following the completion of the sale, the senior vice president now owns 32,648 shares of the company’s stock, valued at $6,793,069.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ronald D. Sugar sold 2,000 shares of the company’s stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $206.70, for a total transaction of $413,400.00. Following the sale, the director now directly owns 16,336 shares of the company’s stock, valued at approximately $3,376,651.20. The disclosure for this sale can be found here. Insiders have sold 17,851 shares of company stock valued at $3,671,900 in the last ninety days. 0.25% of the stock is currently owned by company insiders.
Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, July 30th. The medical research company reported $3.97 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.58 by $0.39. The company had revenue of $5.87 billion during the quarter, compared to analysts’ expectations of $5.67 billion. Amgen had a net margin of 33.78% and a return on equity of 76.17%. Amgen’s quarterly revenue was down 3.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.83 earnings per share. Equities analysts predict that Amgen, Inc. will post 14.31 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, September 6th. Investors of record on Thursday, August 15th were given a dividend of $1.45 per share. The ex-dividend date was Wednesday, August 14th. This represents a $5.80 annualized dividend and a yield of 2.97%. Amgen’s dividend payout ratio is 40.28%.
Several research firms have commented on AMGN. Leerink Swann set a $189.00 price objective on shares of Amgen and gave the company a “hold” rating in a report on Monday. BMO Capital Markets set a $240.00 price objective on shares of Amgen and gave the company a “buy” rating in a report on Monday. Evercore ISI reiterated a “hold” rating on shares of Amgen in a report on Sunday, August 11th. BidaskClub downgraded shares of Amgen from a “hold” rating to a “sell” rating in a report on Thursday, September 12th. Finally, William Blair reiterated a “hold” rating on shares of Amgen in a report on Friday, August 30th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and nine have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $217.41.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Recommended Story: Exchange-Traded Funds (ETFs)
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.